Neck Pain, Posterior
Conditions
Brief summary
This study evaluates the effect of high-velocity low-amplitude thrust (HVLAT) manipulation to the cervical spine on neuropeptide expression as determined by the plasma concentration of oxytocin, neurotensin, orexin A and cortisol; and Examine the effect of HVLAT manipulation on pain perception in symptomatic females with non-specific mechanical cervical spine pain
Detailed description
A high-velocity low-amplitude thrust (HVLAT) manipulation or commonly known as a spinal manipulation, is an intervention frequently used by physical therapists and other healthcare practitioners as an alternative treatment to help relieve spinal pain The mechanism by which HVLAT manipulation modulates pain remains undefined, although this does not contradict the clinical effects from HVLAT manipulation. Furthermore, there is evidence that suggests analgesia after HVLAT manipulation. There is a variety of observed and proposed phenomena that can explain the mechanisms for the psychological, mechanical, or neurophysiological responses from a HVLAT manipulation associated with alterations in pain processing or sympathetic and motor systems' excitation.
Interventions
HVLAT will be performed 10 minutes after the first blood draw.
Sham HVLAT will be performed 10 minutes after the first blood draw.
Sponsors
Study design
Intervention model description
Experimental Group (HVLAT manipulation) Control Group (sham HVLAT manipulation)
Eligibility
Inclusion criteria
* 20 - 45 years of age * A score of 10 or more out of 50 on the Neck Disability Index (NDI) questionnaire * Symptoms of pain present for 30 days or less and no pain symptoms below your shoulder
Exclusion criteria
* Serious condition (such as cancer, spondylolisthesis, rheumatoid arthritis, or ankylosing spondylitis) * Cervical spinal stenosis signs (such as incoordination in hands, arms and legs, inability of walking at a brisk pace, or bowel and bladder incontinence) * Nerve root compression (such as changes in sensation, muscle weakness, or decreased reflexes) * Works the night shift * Steroid medication within 3 months * Pregnancy or postpartum * Pending legal action regarding their neck pain * History of whiplash associated disorder and/or cervical spine surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration of Oxytocin | Blood will be drawn 10 minutes prior to HVLAT procedure. | Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration of Neurotensin | Within 10 minutes after consent signature completion | Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA). |
| Plasma Concentration of Orexin A | Within 10 minutes after consent signature completion | Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA). |
| Plasma Concentration of Cortisol | Within 10 minutes after consent signature completion | Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| HVLAT Manipulation An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
HVLAT manipulation: HVLAT will be performed 10 minutes after the first blood draw. | 13 |
| Sham HVLAT Manipulation Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
Sham HVLAT manipulation: Sham HVLAT will be performed 10 minutes after the first blood draw. | 15 |
| Total | 28 |
Baseline characteristics
| Characteristic | Sham HVLAT Manipulation | Total | HVLAT Manipulation |
|---|---|---|---|
| Age, Customized Mean age of participants | 30 years | 37 years | 37 years |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Sex/Gender, Customized | 15 Participants | 28 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 15 |
| other Total, other adverse events | 0 / 13 | 0 / 15 |
| serious Total, serious adverse events | 0 / 13 | 0 / 15 |
Outcome results
Plasma Concentration of Oxytocin
Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Blood will be drawn 10 minutes prior to HVLAT procedure.
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Oxytocin | 154.5 ug/ml | Standard Deviation 0.9 |
| Sham HVLAT Manipulation | Plasma Concentration of Oxytocin | 158.8 ug/ml | Standard Deviation 0.5 |
Plasma Concentration of Oxytocin
Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Blood will be drawn immediately after HVLAT procedure.
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Oxytocin | 185.1 ug/ml | Standard Deviation 0.9 |
| Sham HVLAT Manipulation | Plasma Concentration of Oxytocin | 189.1 ug/ml | Standard Deviation 0.5 |
Plasma Concentration of Cortisol
Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Blood will be drawn immediately after HVLAT procedure.
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Cortisol | 108.1 ug/ml | Standard Deviation 0.8 |
| Sham HVLAT Manipulation | Plasma Concentration of Cortisol | 139.7 ug/ml | Standard Deviation 0.5 |
Plasma Concentration of Cortisol
Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Within 10 minutes after consent signature completion
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Cortisol | 95.8 ug/ml | Standard Deviation 0.8 |
| Sham HVLAT Manipulation | Plasma Concentration of Cortisol | 127.4 ug/ml | Standard Deviation 0.5 |
Plasma Concentration of Neurotensin
Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Within 10 minutes after consent signature completion
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Neurotensin | 116.0 ug/ml | Standard Deviation 1.6 |
| Sham HVLAT Manipulation | Plasma Concentration of Neurotensin | 125.6 ug/ml | Standard Deviation 0.2 |
Plasma Concentration of Neurotensin
Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Blood will be drawn immediately after HVLAT procedure.
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Neurotensin | 136.4 ug/ml | Standard Deviation 1.6 |
| Sham HVLAT Manipulation | Plasma Concentration of Neurotensin | 131.6 ug/ml | Standard Deviation 0.2 |
Plasma Concentration of Orexin A
Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Within 10 minutes after consent signature completion
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Orexin A | 52.2 ug/ml | Standard Deviation 1 |
| Sham HVLAT Manipulation | Plasma Concentration of Orexin A | 62.9 ug/ml | Standard Deviation 0.2 |
Plasma Concentration of Orexin A
Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Time frame: Blood will be drawn immediately after HVLAT procedure.
Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| HVLAT Manipulation | Plasma Concentration of Orexin A | 73.8 ug/ml | Standard Deviation 1 |
| Sham HVLAT Manipulation | Plasma Concentration of Orexin A | 67.3 ug/ml | Standard Deviation 0.2 |